Science that extends life.
Technology that expands horizons.
Two sectors. Both at generation shifts. Both requiring patient capital and domain expertise. Both offering generational return potential.
Longevity Science
For the first time in human history, we understand the biology of ageing well enough to intervene. From senescent cell clearance to epigenetic reprogramming, the scientific toolbox is filling rapidly. We invest in companies translating this science into therapies, diagnostics, and health platforms that extend healthy human lifespan.
Longevity Therapeutics
Senolytics, epigenetic reprogramming, and hallmark-of-aging interventions targeting the biological mechanisms of ageing.
Neurodegenerative Disease
Early diagnostics and therapeutics for Alzheimer's, Parkinson's, and ALS — one of the greatest unmet needs of our time.
Precision Medicine
Genomics, proteomics, and AI-driven drug discovery enabling personalised health interventions at scale.
Diagnostics & Biomarkers
Liquid biopsies, wearable sensors, and AI-powered health monitoring for early disease detection.
Cardiovascular & Metabolic
Novel approaches to heart disease, diabetes, and metabolic syndrome — the leading causes of preventable death.
Regenerative Medicine
Stem cell therapies, organoids, and tissue engineering offering the promise of organ regeneration and repair.
A Cambridge-based biotech developing senolytic therapies targeting p16⁺ senescent cells. Phase I clinical data showing 40% reduction in senescent cell burden. Seed stage at €5M valuation, founded by former Calico and Genentech scientists with 3 Nature publications.
Why now? The longevity inflection
Human Genome Project completed — genomics era begins
mTOR pathway identified as longevity target
Senolytics enter Phase I clinical trials
Altos Labs raises $3B — reprogramming goes mainstream
First longevity drugs in Phase II/III trials
Longevity-focused biotech IPOs, FDA guidance on aging intervention trials
First approved longevity therapeutics reach market
Space Economy
The commercialisation of space is the most significant economic frontier of the 21st century. Plummeting launch costs, miniaturised satellites, and growing government demand are creating massive opportunity across the value chain — from propulsion to in-orbit services to data analytics. We invest in the infrastructure layer of the space economy.
Launch & Propulsion
Next-gen rocket engines, small satellite launchers, and reusable vehicle technology making space access cheaper.
Satellite Constellations
Earth observation, broadband connectivity, and IoT satellite networks enabling a data-rich world.
In-Orbit Manufacturing
Zero-gravity production of pharmaceuticals, materials, and semiconductors — impossible to make on Earth.
Lunar Economy
Infrastructure for lunar resource extraction, surface mobility, and the emerging cislunar supply chain.
Space Defense & Security
Space domain awareness, cyber resilience for satellite networks, and dual-use defense technologies.
Earth Observation & AI
Analytics platforms turning terabytes of satellite imagery into actionable insights for agriculture, climate, and logistics.
Berlin-based small satellite manufacturer producing 100 kg Earth observation satellites at €2M per unit. Series A at €15M valuation. Two satellites successfully launched, generating €5M ARR from ESA and commercial contracts. Proprietary propulsion system with 30% cost advantage.
Why now? The space inflection
SpaceX lands first orbital rocket booster
Starlink broadband constellation launches
James Webb Space Telescope — new era of discovery
Commercial lunar landing — private Moon economy begins
Crewed Mars mission preparation underway
Permanent lunar outpost, Mars surface operations
How we build the portfolio
Diversified across sectors, stages, and geographies — targeting 12–18 portfolio companies.
Sector Split
Stage Allocation
Geography
Our investment selection criteria
Proprietary technology with defensible competitive moat
Founding team with domain expertise (PhD or 5+ years operator experience)
Addressable market >€1B within 10 years
Clear regulatory pathway (especially biotech/aerospace)
Evidence of early traction: data, pilots, or letters of intent
Strong alignment with longevity or space economy thesis
Reasonable valuation relative to stage and traction
Potential for 10×+ return in success scenario
ESG and ethical research standards met
Institutional-quality due diligence process
What we don't invest in
To maintain focus and ensure ELTIF compliance, we exclude:
Financial services, fintech, or insurtech companies
Real estate and property technology
Consumer software without deep tech moat
Companies requiring >€500K initial investment
Pre-revenue companies with >18 months to market
Any sector outside longevity or space economy
Important Investment Considerations
Venture capital investments are high-risk and illiquid. Typical holding period is 7–10 years with no guarantee of returns. Many portfolio companies will fail. Portfolio returns depend on a small number of successful exits. Only invest capital you can afford to lose and don't need for at least 10 years.
Calculate your potential returns
Adjust the sliders to model different investment scenarios. Projections are illustrative only.
Investment Growth Projection
Assumptions: 8% annual hurdle rate, 25% carried interest on profits above hurdle, 1.5% annual management fee deducted from gross proceeds. Projections are illustrative only and not a guarantee of future returns. Venture capital investments are high-risk and illiquid. Capital at risk.
Ready to be part of the future?
Fund I invests equally across longevity and space. Starting from €10,000.
Start Investing